Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 8/20 | 0.52 |
| ▸ | BCR | P11274 | 8/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | CCNC | P24863 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | LSS | P48449 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13605617 | 0.89 | SLC6A7 (0.55) | SLC6A7GRM5ABL1BCRHDAC3 | |
| SCHEMBL13605612 | 0.89 | SLC6A7 (0.55) | SLC6A7GRM5ABL1BCRHDAC3 | |
| SCHEMBL13659588 | 0.88 | NTRK1 (0.55) | DRD3SLC6A7ABL1BCREPHX2 | |
| SCHEMBL13605624 | 0.88 | GRM5 (0.65) | SLC6A7GRM5ABL1BCRHDAC3 | |
| SCHEMBL13605620 | 0.88 | DRD3 (0.49) | DRD3SLC6A7GRM5ABL1BCR | |
| SCHEMBL13605538 | 0.87 | GRM5 (0.67) | SLC6A7GRM5ABL1BCRHDAC3 | |
| SCHEMBL13605489 | 0.87 | GRM5 (0.67) | SLC6A7GRM5ABL1BCRHDAC3 | |
| SCHEMBL1735187 | 0.85 | CCNC (0.63) | SLC6A7GRM5ABL1BCRHDAC3 | |
| SCHEMBL13605613 | 0.85 | HPGD (0.64) | SLC6A7GRM5ABL1BCRHDAC3 | |
| SCHEMBL13605615 | 0.85 | GAA (0.57) | SLC6A7GRM5ABL1BCRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592349-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-09-22 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | DRD3 3468/4885SLC6A7 3445/4885GRM5 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.